PK STUDY OF ANTIRETROVIRAL THERAPY REGIMENS CONTAINING TENFOVIR AND ATAZANIVIR

含替福韦和阿扎尼韦的抗逆转录病毒治疗方案的药代动力学研究

• 批准号: 7603853
• 负责人: MARVIN E BELZER
• 金额: $ 6.19万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603853
• 关键词: Adolescent; Adult; Age; Anti-Retroviral Agents; Atazanavir; Child; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Grant; HIV-1; Hour; Infection; Institution; Kinetics; Label; Measures; Persons; Pharmaceutical Preparations; Publishing; Purpose; Research; Research Personnel; Resources; Ritonavir; Source; Study Subject; Tenofovir; Treatment Protocols; United States National Institutes of Health; antiretroviral therapy; day; young adult

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open-label, 24-hour, single-dose pharmacokinetic study. Persons with HIV-1 infection between the ages of 18 years, 0 days and 24 years, 364 days currently on a stable combination antiretroviral regimen (>/= 28 days) with FDA-approved antiretroviral combination regimens that include tenofovir plus atazanavir/ritonavir and at least one other active antiretroviral drug will be offered participation. The purpose of this study is to measure the pharmacokinetics of atazanavir/ritonavir and tenofovir when used in combination to treat HIV-infected adolescents and young adult subjects and to compare the kinetics in these study subjects with published kinetic profiles in adults and children.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项开放标签，24小时的单剂量药代动力学研究。 患有HIV-1感染的人在18岁，0天和24岁的年龄之间，目前正在稳定的抗逆转录病毒疗法（>/= 28天），其中包括FDA批准的抗逆转录病毒组合疗法，其中包括Tenofovir Plus tenofovir plus tenofovir plus tenazanavir/rititonavir/Ritonavir/Ritonavir/Ritonavir和其他Active AttiveTral Enticret抗逆转录病毒，并提供其他参与。 这项研究的目的是测量Atazanavir/Ritonavir和Tenofovir的药代动力学，用于治疗HIV感染的青少年和年轻成人受试者，并将这些研究对象中的动力学与成人和儿童发表的动力学进行比较。